Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) CEO Steven L. Hoerter sold 21,573 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $12.02, for a total transaction of $259,307.46. Following the completion of the transaction, the chief executive officer now owns 40,927 shares of the company’s stock, valued at $491,942.54. The sale was disclosed in a filing with the SEC, which is available at this link.
Deciphera Pharmaceuticals Stock Down 1.1 %
Shares of NASDAQ DCPH opened at $11.86 on Thursday. The firm’s 50-day moving average price is $12.53 and its 200-day moving average price is $13.54. Deciphera Pharmaceuticals, Inc. has a 52-week low of $9.90 and a 52-week high of $22.76. The company has a market cap of $934.81 million, a PE ratio of -5.05 and a beta of 0.71.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) last issued its quarterly earnings data on Monday, October 30th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.03. Deciphera Pharmaceuticals had a negative net margin of 127.92% and a negative return on equity of 48.99%. The firm had revenue of $43.31 million for the quarter, compared to analysts’ expectations of $39.66 million. During the same quarter in the prior year, the business earned ($0.55) EPS. As a group, equities research analysts anticipate that Deciphera Pharmaceuticals, Inc. will post -2.36 EPS for the current fiscal year.
Hedge Funds Weigh In On Deciphera Pharmaceuticals
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Deciphera Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday. Jonestrading raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Piper Sandler raised shares of Deciphera Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $23.00 in a research report on Monday. Finally, HC Wainwright increased their price objective on shares of Deciphera Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.63.
Read Our Latest Stock Report on DCPH
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
Featured Articles
- Five stocks we like better than Deciphera Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- First Solar, an affordable, high-quality green investment
- 3 Healthcare Dividend Stocks to Buy
- 5 Dow stocks to track during the market correction
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Lean on these stocks during GDP expansion
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
